1. The Safety and Treatment Response of Combination Therapy of Radioimmunotherapy and Radiofrequency Ablation for Solid Tumor: A Study In Vivo
- Author
-
Feng Lu, Hui-Xiong Xu, Le-Hang Guo, Shu-Guang Zheng, and Lin-Na Liu
- Subjects
Time Factors ,Radiofrequency ablation ,medicine.medical_treatment ,Cancer Treatment ,lcsh:Medicine ,Kaplan-Meier Estimate ,Diagnostic Radiology ,law.invention ,Random Allocation ,law ,Interventional Radiology ,Medicine and Health Sciences ,Medicine ,Vx2 tumor ,lcsh:Science ,Solid tumor ,Multidisciplinary ,Radiology and Imaging ,Animal Models ,Combined Modality Therapy ,Tumor Burden ,Treatment Outcome ,surgical procedures, operative ,Oncology ,Research Design ,Radioimmunotherapy ,Catheter Ablation ,Rabbits ,Immunotherapy ,therapeutics ,Research Article ,Treatment response ,Combination therapy ,Clinical Research Design ,Immunology ,Radiation Therapy ,Research and Analysis Methods ,Model Organisms ,Diagnostic Medicine ,In vivo ,Cell Line, Tumor ,Animals ,Animal Models of Disease ,Tomography, Emission-Computed, Single-Photon ,business.industry ,lcsh:R ,Biology and Life Sciences ,Neoplasms, Experimental ,Animal Studies ,Clinical Immunology ,lcsh:Q ,Tomography, X-Ray Computed ,business ,Nuclear medicine - Abstract
OBJECTION: To investigate the safety and treatment response of radioimmunotherapy (RIT) in combination with radiofrequency ablation (RFA) for the treatment of VX2 tumor on rabbit. MATERIALS AND METHODS: A total of 36 rabbits bearing VX2 tumor on the thigh were randomly assigned into 3 groups (group I: 1-2 cm; group II: 2-3 cm; group III: 3-4 cm) and 4 subgroups (A: as control, just puncture the tumor using the RFA electrode without power output; B: RFA alone; C: 131I-chTNT intratumoral injection alone; D: RFA+131I-chTNT intratumoral injection 3 days later). The variation of blood assay, weight and survival among different groups and subgroups were used to assess the treatment safety. Ultrasound (US) was used to monitor and assess the tumor response after treatment. RESULTS: According to the results of the weight and the blood assay among different groups, subgroups, and at two time points (one day before and the 16th day after treatment), no damages to the liver, kidney function and myelosuppression resulting from the treatment were found. No significant differences in survivals among the four subgroups (p = 0.087) were found. In addition, 131I-chTNT did not show significant inhibition effect on VX2 tumor progression according to US measurements. CONCLUSION: 131I-chTNT intratumoral injection alone or in combination with RFA is relatively safe for rabbit without significant toxicity and shows no significant effect on the survival. The treatment response is not as satisfactory as anticipated.
- Published
- 2014